Further studies will be needed to determine whether adult LFS cancers, especially breast cancers, bear the same genomic hallmarks of germline TP53 mutations which we find in this cohort, as well as to assess the clinical utility of precision oncology in the context of LFS. This evidence concerns the gene TP53 and cancer.